M&A revival with a 71% increase in billion-dollar transactions in Q1 2024
Mergers and acquisitions (M&As) in the biopharmaceutical industry involving companies developing drugs showed a 20% increase in total deal volume in the first quarter (Q1) of 2024 compared to Q1 2023, according to leading data and analytics company GlobalData’s Pharma Intelligence Center Deals Database.
Mergers and acquisitions (M&As) in the biopharmaceutical industry involving companies developing drugs showed a 20% increase in total deal volume in the first quarter (Q1) of 2024 compared to Q1 2023, according to leading data and analytics company GlobalData’s Pharma Intelligence Center Deals Database.
What's Your Reaction?
